Asgard Therapeutics to present positive in vivo efficacy data with AT-108 as monotherapy at Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting
- The presentation demonstrates that AT-108 enhances antigen-presentation in cancer cells and overcomes immune evasion, inducing anti-tumor immunity in aggressive tumors as monotherapy or in combination with immune checkpoint inhibitors.
- These findings provide support for the ongoing pre-clinical development of Asgard’s lead product, AT-108, and its advancement toward IND submission.
Lund, Sweden – October 31, 2023 – Asgard Therapeutics, a private biotech company pioneering in-vivo direct reprogramming for cancer immunotherapy, announces today the presentation of a poster showcasing positive in vivo data. These data will be presented at the 38th Annual Meeting of the Society for Immunotherapy of Cancer (SITC), which will take place in San Diego, California November 1-5, 2023.
The poster will showcase data supporting the effectiveness of AT-108, a novel off-the-shelf cancer immunotherapy based on an adenoviral vector encoding a proprietary combination of reprogramming factors, across immune checkpoint inhibitor-resistant tumors with different types of tumor microenvironment. The study’s results highlight the power of AT-108 to induce complete tumor regressions of non-immunogenic tumors, long-term systemic memory and protection against metastatic challenge.
“We are paving the way for the next generation of immune cell therapies bypassing the traditional hurdles of ex-vivo cell manipulation and immunogenic (neo)antigen identification,” said Dr. Fabio Rosa, Co-Founder and Head of Research at Asgard Therapeutics. “Our in vivo data showcases the unique potential of in vivo direct cell reprogramming in cancer immunotherapy and lays the foundation for the ongoing pre-clinical development of AT-108 and its promising path toward IND submission and clinical trials.”
The full abstract is available at Journal for ImmunoTherapy of Cancer, and details of the poster presentation are as follows:
Title: In-situ reprograming of cancer cells to cDC1s elicits complete tumor regression and immune memory as monotherapy
Time: Saturday, Nov 4, 9 am – 8:30 pm
Presenter: Xiaoli Huang, PhD, Project Director Preclinical Pharmacology
Abstract Number: 1204
About Asgard Therapeutics®
Asgard Therapeutics is a private biotech company exploring the application of direct cell reprogramming technologies for cancer immunotherapies. Formed as a spin-off from Lund University, the Company is pioneering a gene therapy approach based on its proprietary reprogramming technology, designed to set in motion immune responses based on the biological properties of professional antigen-presenting cells. Backed by Novo Holdings, Boehringer Ingelheim Venture Fund, and Industrifonden, Asgard Therapeutics aims to build a pipeline of personalized cancer immunotherapies optimized for each unique patient. For more information, please visit: www.asgardthx.com.
For investor relations:
Cristiana Pires, Co-founder, and CEO
+46 (0) 731 566 072
For scientific inquiries:
Fábio Rosa, Co-founder, and Head of Research
+46 (0) 763 059 937